

## Prevalence, antibiotic resistance pattern and identification of extended spectrum beta-lactamase producing *Klebsiella pneumoniae* by phenotypic and genotypic method from various clinical samples

Shireen Rana<sup>1</sup>, Bilal Ahmad Mir<sup>2,\*</sup>, S.B. Siddesh<sup>3</sup>

<sup>1</sup>Tutor, <sup>2</sup>Associate Professor, <sup>3</sup>Professor and HOD, <sup>1</sup>Dept. of Pharmacology, <sup>2,3</sup>Dept. of Microbiology, Khaja Bandanawaz Institute of Medical Sciences, Kalaburagi, Karnataka, India

\*Corresponding Author: Bilal Ahmad Mir

Email: drbilalahmad86@gmail.com

### Abstract

The present study is about ESBL producing *Klebsiella pneumoniae* which is diagnosed by phenotypic and genotypic methods. A total of 5055 properly collected, well labelled samples, received in the Microbiology laboratory were processed following standard protocol. Total 5055 samples, 805 (16.0%) *Klebsiella pneumoniae* were isolated. 226/3415 (6.64%) urine, 218/649 (33.6%) wound, 127/342 (37.1%) blood, 215/604 (35.6%) pus and 18/45(40.0%) sputum samples tested positive for *Klebsiella pneumoniae*. The occurrence of ESBL producers among *Klebsiella pneumoniae* in the current study is 293/805 (36.4%). Highly resistant drugs for *Klebsiella pneumoniae* ESBL isolates were Ampicillin (100%), Piperacillin (100%), Amoxycillin + clavulanic acid (66.2%). Non ESBL producing isolates were less resistant to the same antibiotics. Out of 805 isolated 285 (35.4%) and 293 (36.3%) were identified as ESBL producers by double disc synergy test and phenotypic confirmatory test respectively. Samples identified as ESBL producers were confirmed by E test. Detection of gene among these isolates, single bla gene could be detected in 59 (20.1%), two genes in 71 (24.2%) and three genes in 156 (53.2%) isolates. blaCTX-M-15 was the only gene found in 8 (4%) of the *Klebsiella pneumoniae* isolates tested, whereas blaSHV alone was found in 42 (14.3%) isolates. Among the combination of two bla genes, the combination of blaSHV and blaCTX-M-15 was found in 54 (18.4%) isolates. This study establishes that considerable genetic diversity and variations in the distribution of ESBL producers and their bla genes exist in the clinical isolates of *K. pneumoniae* across Karnataka.

**Keywords:** ESBL, *Klebsiella pneumoniae*, CLSI guidelines, Gene.

### Introduction

Extended spectrum beta lactamases are prevalent all over the globe, and in addition, they are found in a significant percentage of *Klebsiella pneumoniae* strains in certain parts of the world (Florey et al, 1942; Abraham et al, 1941). Members of Enterobacteriaceae family have emerged as one of the major causes of both nosocomial and community acquired infections. Antibiotic like beta lactams (especially extended-spectrum cephalosporins and carbapenems) and flouroquinolones are the major therapeutic options to treat infections caused by the organisms of this family (Canton et al, 2008).

*Klebsiella* species are important opportunistic nosocomial pathogens particularly *Klebsiella pneumoniae* which causes infections like septicemia, urinary tract infections, wound infections, pneumonia. Due to continuous mutations of ESBLs changes in the amino acid configuration near the active site of these beta lactamases occur, which results in the development of new enzymes showing extended substrate profiles. Till now, more than 400 different ESBLs have been identified, and these are divided into three groups: TEM, SHV and CTX-M. Now the most dominant CTX-M type worldwide is CTX-M-15, which is widespread in India (Rossolini et al, 2008; Canton et al, 2012 and Canton et al, 2006).

Determination of ESBL genes, by molecular methods in bacteria that produce ESBL and their antimicrobial resistance patterns can provide applicable information about their epidemiology and risk factors related to their infections. The aim of the study is to detect extended

spectrum beta lactamase producing *Klebsiella pneumoniae* isolated from the clinical samples by phenotypic methods and molecular method using PCR.

### Materials and Methods

The present study was conducted in Khaja Banda Nawaz Institute of Medical Sciences, Gulbarga, extending over a period of 3 year from 2015 to 2018. A total of 5055 properly collected, well labelled samples, received in the Microbiology laboratory were processed following standard protocol. The various samples which were received included urine, pus, wound sputum and blood. Samples were inoculated on nutrient agar (NA), MacConkey's agar (MA), enriched media like blood agar (BA) by streak plate method under all aseptic conditions and incubated at 37°C for 24hours. *Klebsiella pneumoniae* was isolated on the basis of Gram staining and were confirmed and identified to the species level by standard biochemical tests.

**Antimicrobial Susceptibility Testing:** The isolates were tested by the Kirby-Bauer disc diffusion method on Muller Hinton agar using 0.5 McFarland's as the turbidity standard as per CLSI guidelines.

**Detection of ESBL:** *Klebsiella pneumoniae* isolated were tested for ESBL production by CLSI recommended screening and confirmatory methods like phenotypic confirmation method and MIC using E test. Isolates showing inhibition zone size of  $\leq 22$  mm with Ceftazidime (30  $\mu$ g),  $\leq 25$  mm with Ceftriaxone (30  $\mu$ g) and  $\leq 27$  mm with Cefotaxime (30  $\mu$ g) were identified as potential ESBL producers and shortlisted for confirmation of ESBL

production. Resistance to at least one of the antibiotics was considered as positive in the screening test for possible ESBL production as per 2010 CLSI guidelines. Confirmation of ESBL was done by Double Disc Synergy test and Epsilonometer test (E Test).

**Identification of Organism by Genotypic Criteria:** ESBL producing *Klebsiella pneumoniae* strains detected by phenotypic methods were tested for the presence of blaTEM, blaSHV and CTX-M-15 gene by molecular methods using PCR. ESBL producing *Klebsiella pneumoniae* isolates were preserved in 20% glycerol trypticase soy broth and stored at -20°C. These isolates were sub-cultured on Mueller Hinton agar containing cefotaxime (2µg/ml) and assessed for viability and purity.

**Extraction of Plasmid DNA:** Bacterial plasmid was extracted using PureSol Plasmid Extraction Kit (Merck GeNei, Bangalore) as per manufacturer's instructions. The isolates were grown overnight in Luria Bertani broth with cefotaxime (2µg/ml) at 37°C. In a centrifuge vial, 1.5 ml of this culture suspension was taken and centrifuged at 9000 rpm for one minute and the supernatant was discarded. The pellet was re-suspended in 200 µl of solution A and 10 µl of lysozyme. The tubes were placed in a dry bath at 95°C for one minute and immediately cooled on crushed ice for five minutes. The tubes were then centrifuged at 13,000 RPM for 10 minutes and 500 µl of the supernatant was transferred to another vial. To this, 500 µl of isopropanol was added, mixed well and incubated at room temperature for 5 minutes. The vials were then centrifuged for 10 minutes at 13,000 RPM and the supernatant was discarded. The

resulting pellet washed with 150 µl cold 70% ethanol and centrifuged again at 13,000 RPM for 5 minutes. The supernatant was discarded and the pellet was air-dried. The pellet was resuspended in 25 µl of solution B with 2 µl of RNase A and held for five minutes. The tubes were then stored at -20°C until further study.

**Polymerase Chain Reaction (PCR):** blaTEM and blaSHV genes were detected by PCR in two steps; first step involved screening by amplifying a part of these genes and the second step involved amplification of the complete bla gene. Apart from the blaTEM and blaSHV genes, all plasmid DNA samples were also tested for blaCTX-M-15 gene.

## Results

5055 clinical samples from urine wound, blood pus sputum were tested for *Klebsiella pneumoniae* and 16% samples were found to be positive for *Klebsiella pneumoniae*. These positive samples were further tested for ESBL production and out of 805 sample 293 (36.4%) were ESBL producers.

Table 1 displays Isolation of *Klebsiella pneumoniae* from various clinical samples. From total 5055 samples 805 (16.0%) *Klebsiella pneumoniae* were isolated. 226/3415 (6.64%) urine, 218/649 (33.6%) wound, 127/342 (37.1%) blood, 215/604 (35.6%) pus and 18/45(40.0%) sputum samples tested positive for *Klebsiella pneumoniae*. chi-square test was done and the p value was found to be significant.

**Table 1: Isolation of *Klebsiella pneumoniae* from various clinical samples (n = 5055)**

Sample	<i>Klebsiella pneumoniae</i>		Total samples
	Positive (%)	Negative	Number
Urine	227 (6.64)	3188	3415
Wound	218 (33.6)	431	649
Blood	127 (37.1)	215	342
Sputum	18 (40.0)	27	45
Pus	215 (35.6)	389	604
$\chi^2 = 679.768$ ; p value < 0.001			

Table 2 shows the distribution of ESBL production of *Klebsiella pneumoniae* from various clinical samples. Out of 805 samples of *K. pneumoniae* isolates 293 (36.4%) were ESBL producers. From total 227 urine, 218 wound, 127 blood and 215 pus samples tested 85 (37.4%), 78 (35.7), 45

(35.4%), 75 (34.8%) and 75 (34.8%) were positive for ESBL producing *K. pneumoniae* respectively. maximum ESBL producing isolates were obtained from urine followed by wound and blood. however in sputum out of 18 tested samples 10 (55.5%) were positive for ESBL production.

**Table 2: Distribution according to clinical sources of *K. pneumoniae* isolates producing ESBL**

Samples	Number of ESBL producing isolates		
	<i>Klebsiella pneumoniae</i>		
	Tested	Positive (%)	Negative
Urine	227	85 (37.4)	142
Wound	218	78 (35.7)	140
Blood	127	45 (35.4)	82
Sputum	18	10 (55.5)	8
Pus	215	75 (34.8)	140
Total	805	293 (36.4)	512
$\chi^2 = 3.26$ ; P = 0.515			

Table 3 displays the antibiotic resistance pattern of ESBL producing *Klebsiella pneumoniae*. Highly resistant drugs for *K. pneumoniae* ESBL isolates were Ampicillin (100%), Piperacillin (100%), Amoxicillin + clavulanic acid (66.2%). Non ESBL producing isolates were less resistant to the same antibiotics. Significant difference in resistant pattern between ESBL and Non ESBL isolates was found in case of beta lactam drugs Amoxicillin + clavulanic acid, Gentamicin, Amikacin, Ciprofloxacin, Tobramycin, Ofloxacin, Cefuroxime, Co – trimoxazole, Ceftazidime, Ceftriaxone, Piperacillin + Tazobactam, Nitrofurantoin. The ESBL isolates of *K. pneumoniae* were highly resistant to

these set of antibiotics; however, non-ESBL isolates showed relatively higher sensitivity to them. ESBL producers showed high level of resistance to cephalosporins when compared to non-ESBL producers. About 41.9% ESBL producers were resistant to Cefuroxime were as only 14.2% non-ESBL were resistant to the same drug. 34.4% and 10.1% ESBL and non-ESBL producers were resistant to Ceftazidime respectively. 31.0% ESBL and 11.1% non-ESBL were found to be resistant to Ceftriaxone. The most effective drugs found in antibiotic resistance testing against *K. pneumoniae* ESBL isolates were imipenem and Aztreonam showing 0% resistance each.

**Table 3: Antibiotic resistance pattern of *Klebsiella pneumoniae***

Antibiotic	Code	ESBL Producer (n=293)	Non-ESBL Producer (n=512)	P- value based on Chi – square test
		n (%)	n (%)	
Ampicillin	A	293 (100)	144 (28.1)	<0.001
Pipercillin	B	293 (100)	169 (33.0)	<0.001
Amoxicillin + clavulanic acid	C	194 (66.2)	79 (15.4)	<0.001
Gentamicin	D	146 (49.8)	126 (24.6)	<0.001
Amikacin	E	138 (47.0)	109 (21.2)	<0.001
Ciprofloxacin	F	138 (47.0)	207 (40.4)	<0.001
Tobramycin	G	132 (45.0)	102 (19.9)	<0.001
Ofloxacin	H	128 (43.6)	157 (30.6)	<0.001
Cefuroxime	I	123 (41.9)	73 (14.2)	<0.001
Co-trimoxazole	J	114 (38.9)	84 (16.4)	<0.001
Ceftazidime	K	104 (35.4)	52 (10.1)	<0.001
Ceftriaxone	L	91 (31.0)	57 (11.1)	<0.001
Piperacillin + tazobactam	M	78 (26.6)	16 (3.1)	<0.001
Nitrofurantoin	N	54 (18.4)	103 (20.1)	0.561
Aztreonam	O	0	0	-
Imipenem	P	0	0	-

Screening test and phenotypic confirmatory test for ESBL: Out of 805 isolated 285 (35.4%) and 293 (36.3%) were identified as ESBL producers by double disc synergy test and phenotypic confirmatory test respectively. Samples identified as ESBL producers were confirmed by E test (Fig.1). Detection of gene: Among these isolates, single bla gene could be detected in 59 (20.1%), two genes in 71 (24.2%) and three genes in 156 (53.2%) isolates. blaCTX-M-15 was the only gene found in 8 (4%) of the *Klebsiella pneumoniae* isolates tested, whereas blaSHV alone was found in 42 (14.3%) isolates. Among the combination of two bla genes, the combination of blaSHV and blaCTX-M-15 was found in 54 (18.4%) isolates (Table 4).



**Fig. 1: E test ESBL strip showing clear cut ESBL positive organism showing Ceftazidime (TZ) MIC is reduced by > 3 log<sub>2</sub> dilutions (ratio TZ/ TZL, >8) in the presence of clavulanic acid.**

**Table 4: Distribution of bla gene type in ESBL producing *K. pneumoniae* (n = 293)**

bla type gene	Positive (%)	Negative
TEM only	2 (0.7)	291
SHV only	42 (14.3)	251
CTX-M-15 only	15 (5.1)	278
TEM + SHV	3 (1.0)	290
TEM + CTX –M-15	14 (5.0)	279
SHV + CTX – M-15	54 (18.4)	239
TEM + SHV+ CTX – M-15	156 (53.2)	137
No gene	7 (2.3)	286
$\chi^2 = 585.638; p < 0.001$		

## Discussion

The spread of ESBL producing bacteria has become strikingly rapid worldwide, indicating that continuous monitoring systems and effective infection control measures are absolutely require. It is believed that inappropriate and rampant usage of these antibiotics has led to emergence and selection of ESBL producers (Pinto et al, 2004 and Dancer et al, 2001). Restriction in usage of these antibiotics have been shown to be associated with reduction in incidence of ESBL production (Ballow et al, 1992 and Murki et al, 2010). The occurrence of ESBL producers among *Klebsiella pneumoniae* in the current study was 293/805 (36.4%) (Table 2).

Majority of the clinical samples yielding the isolates used in this study came from urine (37.4), wound (35.7%) and blood (35.4%) formed the bulk of the samples that yielded culture of *K. pneumoniae*. In 2009, CLSI introduced two-step procedure for the detection of ESBL producers. In the first step, isolates of *K. pneumoniae* should be screened for resistance to one or more of third-generation indicator cephalosporin (ceftriaxone, cefotaxime, ceftazidime).

In the present study, 35.4% of *K. pneumoniae* were found to be positive for possible production of ESBLs in the screening test. The screening test involved ceftriaxone, cefotaxime, ceftazidime and but not cefpodoxime. In the pilot study, the cefpodoxime disk did not meet the expected quality standard and therefore could not be included.

In the second step recommended by CLSI, isolates that are positive in the screening test are confirmed for ESBL production by clavulanic acid based test. Although ESBLs are inhibited by clavulanic acid, sulbactam and tazobactam, most phenotypic methods are based on clavulanic acid. In this study, both ceftazidime, ceftazidime+clavulanic acid (CAZ/CAC) and cefotaxime, cefotaxime+clavulanic acid (CTX/CEC) disks were used as per CLSI protocols. CTX/CEC disks were able to detect ESBL production in 98.6% of isolates that were positive in the screening test.

CAZ/CAC disks were able to detect ESBLs in only 89.7% of isolates, suggesting that CTX/CEC disks were more sensitive in detecting ESBLs. In this study out of 805 isolates of *Klebsiella pneumoniae*, 293 isolates could be phenotypically confirmed as ESBL producers by the CLSIPCT method.

Prevalence of ESBL producing *K. pneumoniae* was found to be 36.4%. All ESBL producers were uniformly resistant to ceftriaxone, Ceftazidime, cefotaxime, rendering them inappropriate for treatment. None of the ESBL producers tested in this study exhibited susceptibility MIC breakpoint of  $\leq 1$   $\mu\text{g/ml}$  to cefotaxime and ceftriaxone and  $\leq 4$   $\mu\text{g/ml}$  to Ceftazidime. While ESBL-KP was similarly resistant to cefotaxime and ceftriaxone at MIC level of  $\geq 128$   $\mu\text{g/ml}$  in this study, significantly more number of ESBL-KP were resistant to Ceftazidime. In studies from India, susceptibility of ESBL-KP to ceftazidime ranged from 2.5% to 70%. Susceptibility of ESBL-KP to cefotaxime ranged from 10.1% to 30%. In few other studies, none of the ESBL producers were found to be susceptible to cefotaxime or ceftazidime (Vijayakanthi et al, 2013).

MIC90 of cefotaxime, ceftriaxone and Ceftazidime amongst all ESBL producers were  $>128\mu\text{g/ml}$  indicating high level resistance. In contrast to these findings, a Greek study reported slightly higher MIC values of Ceftazidime than cefotaxime (Poulou et al, 2014) among ESBL producers. Even the type of CTX-M ESBL can influence the MIC values. In a Korean study, the MIC90 of cefotaxime among CTX-M-14 and CTX-M-15 ESBL producers were  $>128$   $\mu\text{g/ml}$  but differed with respect to Ceftazidime (Kim S et al, 2014). While the MIC90 of Ceftazidime was 32  $\mu\text{g/ml}$  in CTX-M-14 producers, it was 256  $\mu\text{g/ml}$  in CTX-M-15 ESBL producers. This difference is obviously due to the fact that CTX-M-15 can hydrolyze Ceftazidime better than CTXM- 14.

In this study, plasmids extracted from the bacteria served as templates for PCR. Of the 293 isolates, only 286 (97.6%) *K. pneumoniae* could be confirmed as ESBL producers by the detection of ESBL gene (Table 4). Among seven isolates none of the three ESBL genes neither there combinations were detected A positive phenotypic test could also be possible due to hyperproduction of classical beta-lactamases. Absence of ESBL gene could also be possible due to missing out on the detection of ESBL gene or the loss of encoding plasmid during storage. As reported worldwide, CTX-M-15 type ESBLs predominated *K. pneumoniae* (81.5%) isolates in this study. SHV type ESBLs are derived from the chromosomal SHV beta-lactamases following one or several mutations in the active site of the enzyme. Single bla SHV gene was found in 14.3% of ESBL positive isolates of *K.pneumonia* were as SHV + CTX-M-15 was found in 18.4% isolates. In this study, 2 (0.7%) blaTEM genes were detected among the ESBL producing *K. pneumoniae*. blaTEM genes have been detected in many studies across India but not many had characterized them by DNA sequencing, hence the actual prevalence of TEM ESBLs is unknown.

*K. pneumoniae* (53.2%) isolates harboured all the three genes (blaTEM, blaSHV and blaCTX-M-15), TEM+SHV was detected in 3 (1%) isolates were as TEM + CTX- M-15 was found in 14(5%) of the total isolates. Presence of multiple bla genes is advantageous to *K. pneumoniae* as it confers resistance to multiple class of beta-lactam antibiotics and thereby provide survival advantage.

This study establishes that considerable genetic diversity and variations in the distribution of ESBL producers and their bla genes exist in the clinical isolates of *K. pneumoniae* across Karnataka. Such studies have to be carried on a continuous basis to detect the emergence of newer resistant strains in the region. Regional and national-level surveillance programs conducted on a periodic basis are vital in understanding and documenting the evolution and spread of beta-lactamase mediated resistant bacteria. Genotypic variations among the bacteria in the population may also influence the choice of strategy for their control and outcome.

### Acknowledgement

We the authors are thankful to the participants, department of Microbiology, Pharmacology, IEC, Dean and principal of KBN institute of medical sciences for helping us to conduct this study.

### References

1. Abraham EP, Chain E, Fletcher CM, Florey HW, Gardner AD, Heatley NG, Jennings MA (1941). Further observations on penicillin. *Lancet* II: 177.
2. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. *Diagn Microbiol Infect Dis*. 1992;15:37S-42S.
3. Canton R, Coque TM. The CTX-M beta-lactamase pandemic. *Curr Opin Microbiol*. 2006;9:466-475.
4. Canton R, González AJM, Galán JC. CTX-M Enzymes: Origin and Diffusion. *Front Microbiol*. 2012;3:110-129.
5. Canton, Novais R, Valverde A, Machado E, Peixe I, Baquero F and Coque T M. Prevalence and spread of extended-spectrum  $\beta$ -lactamase producing Enterobacteriaceae in Europe. *Clin Microbiol Infect*. 2008;14:144-153.
6. Clinical and Laboratory Standards Institute (2010). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S20. Wayne, PA, USA: CLSI.
7. Clinical and Laboratory Standards Institute (2014). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. Wayne, PA, USA: CLSI.
8. Dancer SJ. The problem with cephalosporins. *J Antimicrob Chemother*. 2001;48:463-478.
9. Florey HW, Jennings MA. Some Biological Properties of Highly Purified Penicillin. *Br J Exp Pathol*. 1942;23:120-123.
10. Kim S, Sung JY, Cho HH, Kwon KC, Koo SH. Characterization of CTX-M-14- and CTX-M-15-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolates from Urine Specimens in a Tertiary-Care Hospital. *J Microbiol Biotechnol*. 2014;24:765-770.
11. Murki S, Jonnala S, Mohammed F, Reddy A. Restriction of cephalosporins and control of extended spectrum beta-lactamase producing gram negative bacteria in a neonatal intensive care unit. *Indian Pediatr*. 2010;47:785-758.
12. Pinto Pereira LM, Phillips M, Ramlal H, Teemul K, Prabhakar P (2004). Third generation cephalosporin use in a tertiary hospital in Port of Spain, Trinidad: need for an antibiotic policy. *BMC Infect Dis*. 4:59.
13. Poulou A, Grivakou E, Vrioni G, Koumaki V, Pittaras T, Pournaras S. Modified CLSI extended-spectrum  $\beta$ -lactamase (ESBL) confirmatory test for phenotypic detection of ESBLs among Enterobacteriaceae producing various  $\beta$ -lactamases. *J Clin Microbiol*. 2014;52:1483-1489.
14. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. *Clin Microbiol Infect*. 2008;14:33-41.
15. Vijayakanthi N, Bahl D, Kaur N, Maria A, Dubey NK. Frequency and characteristics of infections caused by extended-spectrum beta-lactamase producing organisms in neonates: a prospective cohort study. *Biomed Res Int*. 2013;7(5):62-69.

**How to cite this article:** Rana S, Mir B. A, Siddesh S.B. Prevalence, antibiotic resistance pattern and identification of extended spectrum beta-lactamase producing *Klebsiella pneumoniae* by phenotypic and genotypic method from various clinical samples. *Indian J Pharm Pharmacol*. 2018;5(4):202-206.